US-based ContraVir Pharmaceuticals will issue shares of its common stock and warrants to purchase shares in order to raise funds required for its research and development (R&D), clinical trials and working capital and other general corporate purposes.

Warrants as part of the underwritten public offering will be issued separately.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company also intends to utilise part of the funds to acquire other companies, products or technologies.

Israeli-based biopharmaceutical company UroGen Pharmaceuticals has announced an initial public offering (IPO) of shares of its common stock to raise funds required for its ongoing clinical trials and development, working capital and other general corporate purposes.

The IPO includes an offer of 3.4 million shares priced between $12 and $14 each to raise up to $48.46m in gross proceeds.

See Also:

"German healthcare company Fresenius has reached an agreement with Merck to acquire the latter’s biosimilars business located in Aubonne and Vevey in Canton de Vaud, Switzerland."

Underwriters have a 30-day option to purchase an additional 519,230 shares in case of any over-allotment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also plans to invest part of the proceeds in depository institutions.

German healthcare company Fresenius has reached an agreement with Merck to acquire the latter’s biosimilars business located in Aubonne and Vevey in Canton de Vaud, Switzerland.

The purchase consideration for the transaction is €670m ($718.35m), which includes €170m ($182.27m) in an upfront cash payment and the remaining to be paid based on the achievement of development targets.

Merck’s biosimilars unit is developing a portfolio of biosimilars for oncology and inflammatory disorders.

The transaction is expected to be completed by June.